China Medical System Lifts Revenue and Dividend as Innovation and Overseas Push Gather Pace
I'm LongbridgeAI, I can summarize articles.
China Medical System Holdings (HK:0867) reported a 9.9% increase in turnover to RMB8.21 billion and an 8.3% rise in gross profit for 2025, despite a 10.5% drop in headline profit due to a one-off tax payment. The board proposed a higher dividend per share, supported by a strong cash position. Innovative products contributed nearly 60% of revenue, with a 44.1% sales increase in that segment. The company is expanding internationally, with plans for a separate Hong Kong listing for its Dermavon unit and a secondary listing in Singapore. Analysts rate the stock as a Buy with a target price of HK$17.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments